432 related articles for article (PubMed ID: 34720089)
21. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
22. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
23. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis.
Ma B; Herzog EL; Lee CG; Peng X; Lee CM; Chen X; Rockwell S; Koo JS; Kluger H; Herbst RS; Sznol M; Elias JA
Cancer Res; 2015 Feb; 75(3):487-96. PubMed ID: 25511377
[TBL] [Abstract][Full Text] [Related]
24. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
25. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
26. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1.
Kim KC; Yun J; Son DJ; Kim JY; Jung JK; Choi JS; Kim YR; Song JK; Kim SY; Kang SK; Shin DH; Roh YS; Han SB; Hong JT
Theranostics; 2018; 8(16):4409-4428. PubMed ID: 30214629
[No Abstract] [Full Text] [Related]
27. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
28. A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity.
Albu DI; Wolf BJ; Qin Y; Wang X; Daniel Ulumben A; Su M; Li V; Ding E; Angel Gonzalo J; Kong J; Jadhav R; Kuklin N; Visintin A; Gong B; Schuetz TJ
Oncoimmunology; 2024; 13(1):2316945. PubMed ID: 38379869
[TBL] [Abstract][Full Text] [Related]
29. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract][Full Text] [Related]
30. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
31. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M
Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475
[TBL] [Abstract][Full Text] [Related]
32. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.
Yang PS; Yu MH; Hou YC; Chang CP; Lin SC; Kuo IY; Su PC; Cheng HC; Su WC; Shan YS; Wang YC
Theranostics; 2022; 12(1):340-361. PubMed ID: 34987649
[No Abstract] [Full Text] [Related]
33. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
Shi Y; Li D; He C; Chen X
Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
[TBL] [Abstract][Full Text] [Related]
34. The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
Schonfeld M; Zhao J; Komatz A; Weinman SA; Tikhanovich I
J Biol Chem; 2020 May; 295(20):7126-7137. PubMed ID: 32245889
[TBL] [Abstract][Full Text] [Related]
35. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
Xu YP; Lv L; Liu Y; Smith MD; Li WC; Tan XM; Cheng M; Li Z; Bovino M; Aubé J; Xiong Y
J Clin Invest; 2019 Jul; 129(10):4316-4331. PubMed ID: 31310587
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
38. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
[TBL] [Abstract][Full Text] [Related]
39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
40. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Li T; Niu M; Zhou J; Wu K; Yi M
Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]